JNJ
US EQUITY
Health Care
Pharmaceuticals
CIK: 200406
Johnson & Johnson (JNJ) Quant Factor Diagnostic & Fair Value Model
Johnson & Johnson (Ticker: JNJ) is listed in the Health Care sector (Pharmaceuticals). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$263.81
-1.42%
Latest Close (2026-10-23)
Market Cap: $635.07B
P/E Ratio: 29.1
Momentum Strength
3M / 12M
-0.80%
1M: -2.54%
12M: +36.73%
Quality (ROE)
Point-in-Time
+26.05%
Trailing Return on Equity
Technical Trend
RSI 14
59.0
SMA50: $265.20
SMA200: $245.47
Valuation Multiplier
Trailing
29.1
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
JNJ trades within a typical sector multiple band (29.1x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 7/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 200406 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-28 | 2026-07-23 | - | $5.53B | $11.13B | $2.27 |
| 10-Q | 2025-12-28 | 2026-07-23 | - | - | - | - |
| 10-Q | 2025-06-29 | 2026-07-23 | - | $5.54B | $8.05B | $2.29 |
| 10-Q | 2026-03-29 | 2026-04-22 | - | $5.24B | $2.51B | $2.14 |
| 10-Q | 2025-03-30 | 2026-04-22 | - | $11.00B | $4.17B | $4.54 |
| 10-K | 2025-12-28 | 2026-02-11 | - | $26.80B | $24.53B | $11.03 |
| 10-K | 2024-12-29 | 2026-02-11 | - | $14.07B | $24.27B | $5.79 |
| 10-K | 2023-12-31 | 2026-02-11 | - | $4.05B | $22.79B | $1.67 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Johnson & Johnson (JNJ) valuation multiples, momentum factors, and point-in-time filing conventions.
How should JNJ's current valuation multiple be interpreted? ↓
JNJ trades at a trailing P/E of 29.1x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are JNJ's key momentum and technical factor indicators? ↓
As of the latest close, JNJ shows a 1-month return of -2.54%, 3-month return of -0.80%, and 12-month return of +36.73%, with a 14-day RSI of 59.0. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for JNJ? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can JNJ be incorporated into systematic factor models? ↓
JNJ can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.